摘要
目的:探讨注射用重组人脑利钠肽联合沙库巴曲缬沙坦治疗冠心病心力衰竭患者的临床效果。方法:选择2021年5月—2022年5月黔东南苗族侗族自治州人民医院收治的90例冠心病心力衰竭患者为研究对象,按随机数表法分为两组,各45例。对照组用沙库巴曲缬沙坦治疗,观察组用注射用重组人脑利钠肽联合沙库巴曲缬沙坦治疗。比较两组临床疗效、心功能、血流动力学及不良反应发生情况。结果:观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组心功能指标比较,差异无统计学意义(P>0.05);治疗8周后,两组心率(HR)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)均低于治疗前,左室射血分数(LVEF)高于治疗前,且观察组HR、LVEDD、LVESD低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。治疗前,两组血流动力学指标比较,差异无统计学意义(P>0.05);治疗8周后,两组心排血量(CO)高于治疗前,平均肺毛细血管楔压(MPCWP)、平均肺动脉压(MPAP)均低于治疗前,且观察组CO高于对照组,MPCWP、MPAP低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:注射用重组人脑利钠肽联合沙库巴曲缬沙坦治疗可提高冠心病心力衰竭患者的临床效果,且对其心功能和血流动力学指标均有显著改善作用,安全可靠。
Objective:To study the clinical effect of Recombinant Human Brain Natriuretic Peptide for Injection combined with Sacubitril Valsartan in patients with coronary heart failure and heart failure.Method:A total of 90 patients with CHD and heart failure admitted to People's Hospital of Qiandongnan Miao and Dong Autonomous Prefecture from May 2021 to May 2022 were selected as the study objects and divided into two groups according to random number table method,with 45 cases in each group.The control group was treated with Sacubitril Valsartan,and the observation group was treated with Recombinant Human Brain Natriuretic Peptide for Injection combined with Sacubitril Valsartan.The clinical efficacy,cardiac function,hemodynamics and the occurrence of adverse reactions were compared between the two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in cardiac function indexes between the two groups(P>0.05).After 8 weeks of treatment,heart rate(HR),left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD)in both groups were lower than those before treatment,left ventricular ejection fraction(LVEF)were higher than those before treatment,and HR,LVEDD and LVESD in observation group were lower than those in the control group,and LVEF was higher than that in the control group,the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in hemodynamic indexes between the two groups(P>0.05).After 8 weeks of treatment,cardiac output(CO)in the two groups were higher than those before treatment,mean pulmonary capillary wedge pressure(MPCWP)and mean pulmonary artery pressure(MPAP)were lower than those before treatment,CO in observation group was higher than that in the control group,MPCWP and MPAP were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Recombinant Human Brain Natriuretic Peptide for Injection combined with Sacubitril Valsartan can improve the clinical effect of CHD patients with heart failure,and significantly improve the cardiac function and hemodynamic indexes,which is safe and reliable.
作者
李锋
LI Feng(People's Hospital of Qiandongnan Miao and Dong Autonomous Prefecture,Kaili 556000,China)
出处
《中外医学研究》
2023年第29期144-147,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
冠心病
心力衰竭
沙库巴曲缬沙坦
注射用重组人脑利钠肽
Coronary heart disease
Heart failure
Sacubitril Valsartan
Recombinant Human Brain Natriuretic Peptide for Injection
